Uchida M, Mochizuki E, Ishida S, Ozawa N, Yonemitsu H, Ochiai H, Nakamura H, Kawashiri T, Kato K, Egashira N, Akashi K, Ieiri I.
Usefulness of a Medication Instruction Sheet for Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia.
In Vivo. 2023 Mar;37(2):924-932.
Kimura M, Ogawa E, Harada K, Imamura J, Saio M, Ikura Y, Yatsuhashi H, Murata K, Miura K, Ieiri I, Tanaka A, Kimura K.
Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study.
BMJ Open Gastroenterol. 2022 Nov;9(1):e001001.
Lee MC, Fujita Y, Muraki S, Huang HL, Lee CH, Wang JY, Ieiri I.
Isoniazid level and flu-like symptoms during rifapentine-based tuberculosis preventive therapy: A population pharmacokinetic analysis.
Br J Clin Pharmacol. 2023 Feb;89(2):714-726.
Kimura K, Kanto T, Shimoda S, Harada K, Kimura M, Nishikawa K, Imamura J, Ogawa E, Saio M, Ikura Y, Okusaka T, Inoue K, Ishikawa T, Ieiri I, Kishimoto J, Todaka K, Kamisawa T.
Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study.
Analysis of the thinking process of pharmacists in response to changes in the dispensing environment using the eye-tracking method.
J Pharm Health Care Sci. 2022 Sep 1;8(1):23.
Kurata Y, Muraki S, Hirota T, Araki H, Ieiri I.
Effect of liver cirrhosis on theophylline trough concentrations: A comparative analysis of organ impairment using Child-Pugh and MELD scores.
Br J Clin Pharmacol. 2022 Aug;88(8):3819-3828.
Fujita Y, Murai M, Muraki S, Suetsugu K, Tsuchiya Y, Hirota T, Matsunaga N, Ieiri I.
Population Pharmacokinetic Analysis of Drug-drug Interactions between Perampanel and Carbamazepine Using Enzyme Induction Model in Epileptic Patients
Ther Drug Monit (in press)
Zhang W, Matsukane R, Egashira N, Tsuchiya Y, Fu R, Yamamoto S, Hirota T, Ieiri I
Neuroprotective effects of ibudilast against tacrolimus induced neurotoxicity
Toxicol Appl Pharmacol
2022年8月
第449巻116112
Yamada T, Soda M, Nishida R, Miyake N, Maeshiro Y, Oida Y, Yamashita Y, Egashira N, Shimono N, Kitaichi K, Ieiri I
Simplified daptomycin dosing regimen for adult patients with methicillin-resistant Staphylococcus aureus infections based on population pharmacokinetic analysis
Drug Metab Pharmacokinet
2022年6月
第44巻100444
Uchida M, Kawai R, Hisamitsu R, Mai S, Ishida S, Watanabe H, Kawashiri T, Kato K, Hosohata K, Miyamoto T, Egashira N, Nakamura T, Akashi K, Ieiri I
Evaluation of medication instruction sheets for patients undergoing R-CHOP therapy in non-hodgkin's lymphoma
Usefulness of medication guidance sheets for patients with non-hodgkin's lymphoma receiving ESHAP±R therapy
Anticancer Res
2022年4月
第42巻(4)2053-2060
Matsukane R, Suetsugu K, Hirota T, Ieiri I
Clinical pharmacokinetics and pharmacodynamics of fostamatinib and its active moiety R406
Clin Pharmacokinet
2022年7月
第61巻(7)955-972
Zhang M, Tajima S, Suetsugu K, Hirota T, Tsuchiya Y, Yamauchi T, Yoshimoto G, Miyamoto T, Egashira N, Akashi K, Ieiri I
Development and validation of an LC-MS/MS method to quantify gilteritinib and its clinical application in patients with FLT3 mutation-positive acute myelogenous leukemia
Ther Drug Monit
2022年8月
第44巻(4)592-596
Zhang M, Tajima S, Shigematsu T, Noguchi H, Kaku K, Tsuchimoto A, Okabe Y, Egashira N, Ieiri I
Development and validation of an LC-MS/MS method to simultaneously measure tacrolimus and everolimus concentrations in kidney allograft biopsies after kidney transplantation
